Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.

[1]  M. Kamm,et al.  Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review , 2020, Journal of gastroenterology and hepatology.

[2]  S. Hanauer,et al.  S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study , 2020 .

[3]  Steven J Brown,et al.  Magnetic resonance enterography for predicting the clinical course of Crohn's disease strictures , 2020, Journal of gastroenterology and hepatology.

[4]  M. Silverberg,et al.  Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. , 2020, The lancet. Gastroenterology & hepatology.

[5]  B. Weiss,et al.  Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. , 2019, Inflammatory bowel diseases.

[6]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[7]  M. Parkes,et al.  Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. , 2019, The lancet. Gastroenterology & hepatology.

[8]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[9]  I. Ordás,et al.  Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease. , 2018, Gastroenterology.

[10]  S. Vermeire,et al.  Risk Stratification for Surgery in Stricturing Ileal Crohn’s Disease: The BACARDI Risk Model , 2018, Journal of Crohn's & colitis.

[11]  D. Hommes,et al.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.

[12]  S. Bonovas,et al.  Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  C. Lambert,et al.  Medical Therapies for Stricturing Crohn’s Disease: Efficacy and Cross-Sectional Imaging Predictors of Therapeutic Failure , 2017, Digestive Diseases and Sciences.

[14]  Steven J Brown,et al.  Crohn's disease management after intestinal resection: a randomised trial , 2015, The Lancet.

[15]  E. Louis,et al.  Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study , 2015, Gut.

[16]  S. Morita,et al.  Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn’s disease , 2014, BMC Research Notes.

[17]  F. Remzi,et al.  Crohn's disease complicated by strictures: a systematic review , 2013, Gut.

[18]  Jordi Rimola,et al.  Magnetic resonance imaging for evaluation of Crohn's disease: Validation of parameters of severity and quantitative index of activity , 2011, Inflammatory bowel diseases.

[19]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[20]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[21]  L. Peyrin-Biroulet,et al.  The Natural History of Adult Crohn's Disease in Population-Based Cohorts , 2010, The American Journal of Gastroenterology.

[22]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[23]  M. Vatn,et al.  Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN study) , 2007, Scandinavian journal of gastroenterology.

[24]  S. Hanauer,et al.  Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine , 2005, Alimentary pharmacology & therapeutics.

[25]  P. Rutgeerts,et al.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.

[26]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[27]  A. Kornbluth,et al.  Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication , 2000 .

[28]  D. Present,et al.  Short term infliximab toxicity in crohn's disease , 2000 .

[29]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[30]  C. Hirota,et al.  Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn’s Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme , 2017, Journal of Crohn's & colitis.

[31]  G. Van Assche,et al.  A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohn's Disease , 2017, Inflammatory bowel diseases.

[32]  E. Louis,et al.  Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. , 2015, Gastroenterology.

[33]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[34]  Province,et al.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.